艾伯维 (AbbVie) 在完成收购ImmunoGen 后更新了第一季度盈利预期，反映了每股 0.04 美元的摊薄影响。 AbbVie updates first-quarter earnings outlook after completing ImmunoGen acquisition, reflecting $0.04/share dilutive impact.

制药公司艾伯维(AbbVie)因近期收购癌症药物制造商ImmunoGen的影响，调整了2024年第一季度的盈利预期。 AbbVie, a pharmaceutical company, has revised its Q1 2024 earnings outlook due to the impact of its recent acquisition of ImmunoGen, a cancer drugmaker. 调整后的摊薄每股收益目前预计为 2.26 美元至 2.30 美元，之前的范围为 2.30 美元至 2.34 美元。 The adjusted diluted EPS is now expected to be between $2.26 and $2.30, compared to the previous range of $2.30 to $2.34. 此次更新考虑了收购ImmunoGen 带来的每股0.04 美元的稀释影响。 The update takes into account a $0.04/share dilutive impact from the ImmunoGen acquisition. 该交易完成后，ImmunoGen 股票停止在纳斯达克证券交易所交易。 The deal's completion has led to ImmunoGen stock ceasing trading on the Nasdaq stock exchange. 尽管进行了这一修订，艾伯维仍重申其 2024 年全年调整后摊薄每股收益指导为 11.05 美元至 11.25 美元。 Despite this revision, AbbVie has reaffirmed its full-year 2024 adjusted diluted EPS guidance of $11.05 to $11.25.